ERAP1 Inhibition to Generate Neoantigens & Drive Anti-Tumour Cell Killing

Time: 12:00 pm
day: Day Two


  • Targeting the endoplasmic reticulum in the antigen presentation pathway to create novel neoantigens in cancer
  • Increasing tumour visibility and extending the therapeutic benefit of immunotherapy to many more cancer patients
  • Presenting Grey Wolf’s 1st in class ERAP1 inhibitor as a therapeutic pipeline for opportunities